|
hi, spätestens in einem jahr wird geron explodieren, den das jahr, wo die hohen umsätze generiert werden rückt immer näher. Geron Corporation Reports 2000 Third Quarter Financial Results and Events FRIDAY, NOVEMBER 10, 2000 7:31 AM - BusinessWire MENLO PARK, Calif., Nov 10, 2000 (BW:GERN) today reported financial results and events for the three and nine months ended September 30, 2000. For the quarter, the company reported operating revenue of $1.8 million and operating expenses of $8.1 million compared to $1.3 million and $8.2 million, respectively, for the comparable period in 1999. Net loss for the period was $4.9 million or $(0.23) per share compared to $6.9 million or $(0.42) per share in 1999. For the nine months ended September 30, 2000, the company reported operating revenue of $4.8 million and operating expenses of $26.7 million compared to $4.1 million and $42.9 million, respectively, for the comparable 1999 period. Net loss for the nine month period was $29.9 million or $(1.45) per share compared to $38.4 million or $(2.55) per share in 1999. Revenues recognized during the third quarter of 2000 include research support payments under the Pharmacia and Kyowa Hakko collaborative agreements and royalties received under various diagnostic and research products licensing agreements. Excluding the effect of the acquisition expense in 1999, operating expenses for the nine months ended September 30, 2000 have increased compared to the comparable periods in 1999. Research and development expenses increased primarily as a result of research funding at the Roslin Institute. General and administrative expenses increased as a result of consulting contracts and increased accounting and legal costs relating to various transactions. In September 2000, the company entered into an agreement with an institutional investor for an equity financing facility covering the sale of up to $50.0 million of the company`s common stock over 24 months. The company controls the amount and timing of each sale of stock. Geron is a biopharmaceutical company focused on discovering, developing and commercializing therapeutic and diagnostic products for applications in oncology, drug discovery and regenerative medicine. Geron`s product development programs are based upon three patented core technologies: telomerase, human pluripotent stem cells and nuclear transfer. The company desires to take advantage of the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Specifically, the company wishes to alert readers that the matters discussed in this press release may constitute forward-looking statements that are subject to certain risks and uncertainties, including risks inherent in research and development efforts, reliance on collaborative partners, enforcement of patents and proprietary rights, need for future capital, potential competition and uncertainty of regulatory approvals or clearances. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect the company`s financial results is included in the company`s Quarterly Report on Form 10-Q for the quarter ended September 30, 2000. Contact: Geron Corporation Olivia K. Bloom Controller 650-473-7700 |
|
| aus der Diskussion: | DIESER BIOTECH-WERT WIRD SICH IN DEN NÄCHSTEN JAHREN VERZEHNFACHEN!! |
| Autor (Datum des Eintrages): | Z:PO (12.12.00 23:24:07) |
| Beitrag: | 7 von 13 (ID:2518962) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |